OGIVRI 150 mg/7.4mL
trastuzumab-dkst · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Biocon Biologics Inc.
OGIVRI is a injection, powder, lyophilized, for solution containing trastuzumab-dkst at 150 mg/7.4mL, taken intravenous. Manufactured by Biocon Biologics Inc..
Key Facts
- Brand Name
- OGIVRI
- Generic Name
- trastuzumab-dkst
- NDC Code (Product)
83257-001- Manufacturer
- Biocon Biologics Inc.
- Strength
- 150 mg/7.4mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761074
- Drug Class
- HER2/neu Receptor Antagonist [EPC]
- Marketing Start
- 10/01/2023
Recall History
No Recall HistoryFrequently Asked Questions
What is OGIVRI used for?
OGIVRI contains trastuzumab-dkst. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.
Is OGIVRI a controlled substance?
OGIVRI is not classified as a controlled substance by the DEA.
What is the generic name for OGIVRI?
The generic name for OGIVRI is trastuzumab-dkst. There are no other listed brand versions of trastuzumab-dkst.
What is the NDC code for OGIVRI 150 mg/7.4mL?
The NDC (National Drug Code) for OGIVRI 150 mg/7.4mL is 83257-001, listed by Biocon Biologics Inc..
Other OGIVRI Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)